Exagen Inc (XGN) - Net Assets
Based on the latest financial reports, Exagen Inc (XGN) has net assets worth $14.43 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($51.96 Million) and total liabilities ($37.52 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore XGN total asset value for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $14.43 Million |
| % of Total Assets | 27.78% |
| Annual Growth Rate | 10.4% |
| 5-Year Change | -79.46% |
| 10-Year Change | N/A |
| Growth Volatility | 1061.79 |
Exagen Inc - Net Assets Trend (2012–2025)
This chart illustrates how Exagen Inc's net assets have evolved over time, based on quarterly financial data. Check Exagen Inc (XGN) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Exagen Inc (2012–2025)
The table below shows the annual net assets of Exagen Inc from 2012 to 2025. For live valuation and market cap data, see Exagen Inc market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $17.45 Million | +82.90% |
| 2024-12-31 | $9.54 Million | -57.96% |
| 2023-12-31 | $22.69 Million | -46.55% |
| 2022-12-31 | $42.46 Million | -50.01% |
| 2021-12-31 | $84.94 Million | +103.01% |
| 2020-12-31 | $41.84 Million | -24.83% |
| 2019-12-31 | $55.66 Million | +926.54% |
| 2018-12-31 | $-6.73 Million | -45.19% |
| 2017-12-31 | $-4.64 Million | +79.09% |
| 2015-12-31 | $-22.18 Million | -57.83% |
| 2014-12-31 | $-14.06 Million | -3216.63% |
| 2013-12-31 | $451.00K | -90.65% |
| 2012-12-31 | $4.82 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Exagen Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 25349000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $23.00K | 0.13% |
| Other Components | $331.71 Million | 1901.01% |
| Total Equity | $17.45 Million | 100.00% |
Exagen Inc Competitors by Market Cap
The table below lists competitors of Exagen Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kumho Petro Chemical Co Ltd
KO:011785
|
$103.68 Million |
|
Darya-Varia Laboratoria Tbk
JK:DVLA
|
$103.69 Million |
|
Dongyang E&P Inc
KQ:079960
|
$103.82 Million |
|
SinoMedia Holding Limited
F:SJY
|
$103.83 Million |
|
ReFuels N.V.
OL:REFL
|
$103.61 Million |
|
Active Biotech AB
ST:ACTI
|
$103.60 Million |
|
Y.C.C. Parts MFG Co Ltd
TW:1339
|
$103.57 Million |
|
Synchronoss Technologies Inc
NASDAQ:SNCR
|
$103.56 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Exagen Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 9,540,000 to 17,449,000, a change of 7,909,000 (82.9%).
- Net loss of 19,951,000 reduced equity.
- New share issuances of 22,025,000 increased equity.
- Other factors increased equity by 5,835,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-19.95 Million | -114.34% |
| Share Issuances | $22.02 Million | +126.22% |
| Other Changes | $5.83 Million | +33.44% |
| Total Change | $- | 82.90% |
Book Value vs Market Value Analysis
This analysis compares Exagen Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.78x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.03x to 5.78x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $136.19 | $4.68 | x |
| 2013-12-31 | $8.40 | $4.68 | x |
| 2014-12-31 | $-249.38 | $4.68 | x |
| 2015-12-31 | $-353.27 | $4.68 | x |
| 2017-12-31 | $-73.61 | $4.68 | x |
| 2018-12-31 | $-106.88 | $4.68 | x |
| 2019-12-31 | $4.43 | $4.68 | x |
| 2020-12-31 | $3.31 | $4.68 | x |
| 2021-12-31 | $5.32 | $4.68 | x |
| 2022-12-31 | $2.49 | $4.68 | x |
| 2023-12-31 | $1.28 | $4.68 | x |
| 2024-12-31 | $0.52 | $4.68 | x |
| 2025-12-31 | $0.81 | $4.68 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Exagen Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -114.34%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -29.97%
- • Asset Turnover: 1.15x
- • Equity Multiplier: 3.33x
- Recent ROE (-114.34%) is above the historical average (-286.63%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -151.89% | -790.93% | 0.08x | 2.34x | $-7.81 Million |
| 2013 | -2992.46% | -441.77% | 0.19x | 36.48x | $-13.54 Million |
| 2014 | 0.00% | -128.45% | 0.68x | 0.00x | $-13.58 Million |
| 2015 | 0.00% | -106.89% | 1.23x | 0.00x | $-16.96 Million |
| 2017 | 0.00% | -95.61% | 1.31x | 0.00x | $-25.17 Million |
| 2018 | 0.00% | -24.70% | 1.12x | 0.00x | $-7.34 Million |
| 2019 | -21.63% | -29.81% | 0.46x | 1.59x | $-17.60 Million |
| 2020 | -39.88% | -39.75% | 0.54x | 1.87x | $-20.87 Million |
| 2021 | -31.61% | -55.59% | 0.39x | 1.45x | $-35.34 Million |
| 2022 | -111.60% | -104.00% | 0.53x | 2.03x | $-51.63 Million |
| 2023 | -104.38% | -45.08% | 0.92x | 2.51x | $-25.96 Million |
| 2024 | -158.44% | -27.17% | 1.25x | 4.68x | $-16.07 Million |
| 2025 | -114.34% | -29.97% | 1.15x | 3.33x | $-21.70 Million |
Industry Comparison
This section compares Exagen Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $523,415,420
- Average return on equity (ROE) among peers: -182.94%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Exagen Inc (XGN) | $14.43 Million | -151.89% | 2.60x | $103.65 Million |
| Agilent Technologies Inc (A) | $5.84 Billion | 21.21% | 0.84x | $39.22 Billion |
| Advanced Biomed Inc. Common Stock (ADVB) | $976.24K | -188.19% | 0.03x | $8.80 Million |
| Applied DNA Sciences Inc (APDN) | $754.50K | -1549.75% | 6.47x | $3.99 Million |
| Biodesix Inc (BDSX) | $-2.46 Million | 0.00% | 0.00x | $210.64 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-4.04 Million | 0.00% | 0.00x | $2.97 Million |
| Biocept Inc. (BIOCQ) | $37.48 Million | -7.53% | 0.61x | $262.60 |
| BillionToOne, Inc. Class A Common Stock (BLLN) | $167.75 Million | -24.78% | 0.80x | $4.57 Billion |
| Burning Rock Biotech Ltd (BNR) | $-891.49 Million | 0.00% | 0.00x | $78.88 Million |
| CareDx Inc (CDNA) | $29.49 Million | -46.47% | 0.89x | $1.42 Billion |
| Check Cap Ltd (CHEK) | $50.69 Million | -33.94% | 0.10x | $9.42 Million |
About Exagen Inc
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's lead test… Read more